Capital One Initiates Coverage On Protagonist Therapeutics with Overweight Rating
Protagonist Therapeutics, Inc. +0.77%
Protagonist Therapeutics, Inc. PTGX | 42.00 | +0.77% |
Capital One analyst Tim Chiang initiates coverage on Protagonist Therapeutics (NASDAQ:
PTGX) with a Overweight rating.